Filing search / Lyell Immunopharma, Inc. / "Litigation" / Page 3

8-K

8aqmz n14i4rspq

24 Oct 22

Termination of a Material Definitive Agreement

5:20pm

8-K

EX-99.1

2rc zsvb4jd735ol378r

6 Oct 22

Regulation FD Disclosure

4:37pm

S-3ASR

EX-4.4

kbu bik9gii

4 Aug 22

Automatic shelf registration

5:29pm

S-3ASR

xkdmk4kr1z la7erswdz

4 Aug 22

Automatic shelf registration

5:29pm

S-3ASR

EX-1.2

1yi8qm3q4lzgz3zguw

4 Aug 22

Automatic shelf registration

5:29pm

8-K

EX-99.1

9e54qo5yq8v

4 Aug 22

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

4:16pm

8-K

EX-99.1

f4fy71hhy

10 May 22

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

4:14pm

S-8

iftv5w g1s0i8maqb

29 Mar 22

Registration of securities for employees

4:56pm

10-K

rpx4pnobslrw2z6h l0b

29 Mar 22

Annual report

4:20pm

8-K

EX-99.1

x9ohu

29 Mar 22

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

4:15pm

8-K

EX-99.2

bmx432yx1i vz

17 Dec 21

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

4:02pm

8-K

acf 8mycxb1

17 Dec 21

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

4:02pm

8-K

EX-99.1

u95wu

17 Dec 21

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

4:02pm

8-K

EX-99.1

e3dz9nkshy 0fm0

12 Nov 21

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

8:20am

10-Q

cnyv70xw

12 Aug 21

Quarterly report

5:07pm

8-K

EX-99.1

al6jt0 wetwo

12 Aug 21

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

4:18pm

S-8

pr4wtp1dgolnj

21 Jun 21

Registration of securities for employees

5:08pm